Investment analysts at Huntington Sec began coverage on shares of Sabra Healthcare REIT (NASDAQ:SBRA – Get Free Report) in a research report issued to clients and investors on Monday, Zacks reports. The brokerage set a “strong-buy” rating on the real estate investment trust’s stock.
Other equities analysts have also issued reports about the company. UBS Group cut their price target on Sabra Healthcare REIT from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Tuesday, October 13th. Wells Fargo & Company decreased their price objective on Sabra Healthcare REIT from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Monday, October 19th. Huntington started coverage on Sabra Healthcare REIT in a report on Thursday, September 10th. They set an “outperform” rating and a $23.00 price objective on the stock. Mizuho set a $21.00 target price on Sabra Healthcare REIT in a research note on Monday, August 31st. Finally, Truist Financial lifted their target price on Sabra Healthcare REIT from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.50.
Read Our Latest Report on Sabra Healthcare REIT
Sabra Healthcare REIT Stock Performance
NASDAQ SBRA opened at $20.35 on Monday. The firm has a market cap of $5.20 billion, a P/E ratio of 72.68, a price-to-earnings-growth ratio of 1.79 and a beta of 0.68. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.95. The company’s 50 day moving average is $19.85 and its 200-day moving average is $19.97. Sabra Healthcare REIT has a 12-month low of $17.53 and a 12-month high of $22.77.
Sabra Healthcare REIT (NASDAQ:SBRA – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The real estate investment trust reported $0.11 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.05). Sabra Healthcare REIT had a return on equity of 2.56% and a net margin of 7.78%. The business had revenue of $249.57 million during the quarter, compared to the consensus estimate of $236.64 million. During the same period last year, the business posted $0.38 earnings per share. The firm’s quarterly revenue was up 31.4% on a year-over-year basis. Sell-side analysts predict that Sabra Healthcare REIT will post 1.52 earnings per share for the current year.
Insider Activity at Sabra Healthcare REIT
In other news, CEO Richard Matros sold 200,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $20.83, for a total value of $4,166,000.00. Following the transaction, the chief executive officer owned 1,657,686 shares of the company’s stock, valued at approximately $34,529,599.38. This represents a 10.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.09% of the stock is owned by company insiders.
Institutional Investors Weigh In On Sabra Healthcare REIT
Several large investors have recently added to or reduced their stakes in SBRA. Principal Financial Group Inc. increased its position in shares of Sabra Healthcare REIT by 0.4% during the 1st quarter. Principal Financial Group Inc. now owns 25,052,121 shares of the real estate investment trust’s stock valued at $481,755,000 after purchasing an additional 98,770 shares during the last quarter. Lasalle Investment Management Securities LLC raised its holdings in shares of Sabra Healthcare REIT by 8.2% during the 1st quarter. Lasalle Investment Management Securities LLC now owns 3,824,622 shares of the real estate investment trust’s stock valued at $73,547,000 after buying an additional 290,405 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Sabra Healthcare REIT by 7.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,725,337 shares of the real estate investment trust’s stock valued at $71,640,000 after buying an additional 269,793 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Sabra Healthcare REIT by 6.8% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,208,600 shares of the real estate investment trust’s stock worth $61,701,000 after buying an additional 203,226 shares during the last quarter. Finally, Rush Island Management LP bought a new stake in Sabra Healthcare REIT in the 1st quarter worth approximately $30,735,000. Institutional investors own 99.40% of the company’s stock.
Key Stories Impacting Sabra Healthcare REIT
Here are the key news stories impacting Sabra Healthcare REIT this week:
- Positive Sentiment: Sabra raised its 2026 guidance: EPS is now projected at $1.54–$1.55, above the $1.52 consensus, and the midpoint of normalized FFO guidance increased by $0.005 per share. Management also expects 7%–8% year-over-year earnings growth. Sabra Health Care: 3 Key Takeaways for Long-Term Investors
- Positive Sentiment: Third-quarter revenue of about $249.6 million exceeded analyst estimates of $236.6 million and rose 31.4% year over year. Adjusted FFO also topped consensus, according to Zacks. Sabra Healthcare Tops Q3 FFO and Revenue Estimates
- Positive Sentiment: Senior-housing operating portfolio occupancy reached 89.2%, supporting the company’s growth outlook. Sabra also declared a quarterly dividend of $0.30 per share, equivalent to a 6.0% yield based on the provided data. Sabra Reports Third Quarter 2026 Results; Updates 2026 Guidance
- Neutral Sentiment: Sabra aims to increase its senior housing operating portfolio (SHOP) to 50% of its portfolio by year-end 2027, while management sees further upside from nursing-home asset optimization and lease negotiations. The strategy offers growth potential but depends on execution. Sabra Expects Earnings Growth and Targets More SHOP Exposure
- Negative Sentiment: Reported third-quarter net income was $0.11 per diluted share, below the $0.16 analyst consensus and down from $0.38 a year earlier. This earnings miss may temper the positive impact of stronger revenue, FFO, and guidance. Sabra Q3 Earnings Results
Sabra Healthcare REIT Company Profile
Sabra Healthcare REIT, Inc is a self-managed real estate investment trust that owns and invests in healthcare-related real estate. The company focuses primarily on properties used for skilled nursing and transitional care, senior housing, behavioral health, specialty hospitals and other healthcare services.
Sabra leases properties to healthcare operators and also provides capital through loans, joint ventures and other real estate investments. Its portfolio is designed to support a range of care settings, including facilities serving seniors, patients requiring rehabilitation and individuals receiving behavioral healthcare.
Founded in 2010 and headquartered in Irvine, California, Sabra has expanded through acquisitions, development investments and strategic transactions, including its 2017 combination with Care Capital Properties.
Featured Articles
- Five stocks we like better than Sabra Healthcare REIT
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Sabra Healthcare REIT Right Now?
Before you consider Sabra Healthcare REIT, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Sabra Healthcare REIT wasn’t on the list.
While Sabra Healthcare REIT currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. “Physical AI” is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
